Anthrax tests
This article was originally published in The Gray Sheet
Executive Summary
U.S. Office of Science and Technology's July 19 recommendation against rapid anthrax field test use did not include Response Biomedical's RAMP even though the firm's competitors were included under the scope of the document, the firm claims. The test was commercially launched in May (1"The Gray Sheet" June 3, 2002, In Brief)...
You may also be interested in...
Response Biomedical
Rapid, on-site anthrax detection system based on the firm's RAMP technology is launched May 29. Intended for use by emergency responders, the environmental test can distinguish "between a hoax and a potentially infectious dose" in under 15 minutes, the firm claims. Vancouver-based Response hopes to place several hundred of the $10,000 systems by year-end, estimating a $500 mil. U.S. anthrax detection market within two years. The firm is in the process of signing co-marketing and distribution agreements. Separately, Response plans 510(k) submissions for CK-MB and troponin 1 analyte cardiac marker tests by the end of 2002. The RAMP reader was cleared in January for general clinical use along with a myoglobin cardiac marker test...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.